The Experts below are selected from a list of 140469 Experts worldwide ranked by ideXlab platform

Mari Hashitate Dallas - One of the best experts on this subject based on the ideXlab platform.

  • gamma delta t Cell reconstitution is associated with fewer infections and improved event free survival after hematopoietic stem Cell transplantation for pediatric leukemia
    Biology of Blood and Marrow Transplantation, 2015
    Co-Authors: Ross Perko, Guolian Kang, Anusha Sunkara, Wing Leung, Paul G Thomas, Mari Hashitate Dallas
    Abstract:

    Abstract After hematopoietic stem Cell transplantation (HSCT), successful engraftment and immune Recovery is necessary to protect the patient from relapse and infection. Many studies highlight the importance of conventional αβ T Cell Recovery after HSCT, but the impact of γδ T Cell Recovery has not been well described. Here, we investigate the Recovery of γδ T Cells in 102 pediatric patients with acute leukemia in first clinical remission who underwent allogeneic HSCT at St. Jude Children's Research Hospital from 1996 to 2011. Mean patient age was 10.5 ± 5.9 years (range, .6 to 25.2), and mean survivor follow-up was 2.7 ± 1.8 years (range, .12 to 6.0). Diagnoses included 59% patients with acute lymphoblastic leukemia and 41% patients with acute myelogenous leukemia. Multivariate analysis demonstrated significant impact of the maximum number of CD3+, CD4+, and CD8+ T Cells and donor source on the γδ T Cell Recovery (P

  • gamma delta t Cell reconstitution is associated with fewer infections and improved event free survival after hematopoietic stem Cell transplantation for pediatric leukemia
    Biology of Blood and Marrow Transplantation, 2015
    Co-Authors: Ross Perko, Guolian Kang, Anusha Sunkara, Wing Leung, Paul G Thomas, Mari Hashitate Dallas
    Abstract:

    Abstract After hematopoietic stem Cell transplantation (HSCT), successful engraftment and immune Recovery is necessary to protect the patient from relapse and infection. Many studies highlight the importance of conventional αβ T Cell Recovery after HSCT, but the impact of γδ T Cell Recovery has not been well described. Here, we investigate the Recovery of γδ T Cells in 102 pediatric patients with acute leukemia in first clinical remission who underwent allogeneic HSCT at St. Jude Children's Research Hospital from 1996 to 2011. Mean patient age was 10.5 ± 5.9 years (range, .6 to 25.2), and mean survivor follow-up was 2.7 ± 1.8 years (range, .12 to 6.0). Diagnoses included 59% patients with acute lymphoblastic leukemia and 41% patients with acute myelogenous leukemia. Multivariate analysis demonstrated significant impact of the maximum number of CD3 + , CD4 + , and CD8 + T Cells and donor source on the γδ T Cell Recovery ( P P P P P  = .026 and P  = .02, respectively). We found the probability of infections for patients with an elevated number of γδ T Cells was significantly lower compared with patients with low or normal γδ T Cells after HSCT (18% versus 54%; P  = .025). Bacterial infections were not observed in patients with elevated γδ T Cells. Finally, event-free survival was significantly higher in patients with enhanced γδ T Cell reconstitution compared with patients with low/normal γδ T Cell reconstitution after HSCT (91% versus 55%; P  = .04). Thus, γδ T Cells may play an important role in immune reconstitution after HSCT.

Wing Leung - One of the best experts on this subject based on the ideXlab platform.

  • gamma delta t Cell reconstitution is associated with fewer infections and improved event free survival after hematopoietic stem Cell transplantation for pediatric leukemia
    Biology of Blood and Marrow Transplantation, 2015
    Co-Authors: Ross Perko, Guolian Kang, Anusha Sunkara, Wing Leung, Paul G Thomas, Mari Hashitate Dallas
    Abstract:

    Abstract After hematopoietic stem Cell transplantation (HSCT), successful engraftment and immune Recovery is necessary to protect the patient from relapse and infection. Many studies highlight the importance of conventional αβ T Cell Recovery after HSCT, but the impact of γδ T Cell Recovery has not been well described. Here, we investigate the Recovery of γδ T Cells in 102 pediatric patients with acute leukemia in first clinical remission who underwent allogeneic HSCT at St. Jude Children's Research Hospital from 1996 to 2011. Mean patient age was 10.5 ± 5.9 years (range, .6 to 25.2), and mean survivor follow-up was 2.7 ± 1.8 years (range, .12 to 6.0). Diagnoses included 59% patients with acute lymphoblastic leukemia and 41% patients with acute myelogenous leukemia. Multivariate analysis demonstrated significant impact of the maximum number of CD3+, CD4+, and CD8+ T Cells and donor source on the γδ T Cell Recovery (P

  • gamma delta t Cell reconstitution is associated with fewer infections and improved event free survival after hematopoietic stem Cell transplantation for pediatric leukemia
    Biology of Blood and Marrow Transplantation, 2015
    Co-Authors: Ross Perko, Guolian Kang, Anusha Sunkara, Wing Leung, Paul G Thomas, Mari Hashitate Dallas
    Abstract:

    Abstract After hematopoietic stem Cell transplantation (HSCT), successful engraftment and immune Recovery is necessary to protect the patient from relapse and infection. Many studies highlight the importance of conventional αβ T Cell Recovery after HSCT, but the impact of γδ T Cell Recovery has not been well described. Here, we investigate the Recovery of γδ T Cells in 102 pediatric patients with acute leukemia in first clinical remission who underwent allogeneic HSCT at St. Jude Children's Research Hospital from 1996 to 2011. Mean patient age was 10.5 ± 5.9 years (range, .6 to 25.2), and mean survivor follow-up was 2.7 ± 1.8 years (range, .12 to 6.0). Diagnoses included 59% patients with acute lymphoblastic leukemia and 41% patients with acute myelogenous leukemia. Multivariate analysis demonstrated significant impact of the maximum number of CD3 + , CD4 + , and CD8 + T Cells and donor source on the γδ T Cell Recovery ( P P P P P  = .026 and P  = .02, respectively). We found the probability of infections for patients with an elevated number of γδ T Cells was significantly lower compared with patients with low or normal γδ T Cells after HSCT (18% versus 54%; P  = .025). Bacterial infections were not observed in patients with elevated γδ T Cells. Finally, event-free survival was significantly higher in patients with enhanced γδ T Cell reconstitution compared with patients with low/normal γδ T Cell reconstitution after HSCT (91% versus 55%; P  = .04). Thus, γδ T Cells may play an important role in immune reconstitution after HSCT.

Hergen Spits - One of the best experts on this subject based on the ideXlab platform.

  • flt3 ligand expands lymphoid progenitors prior to Recovery of thymopoiesis and accelerates t Cell reconstitution after bone marrow transplantation
    Journal of Immunology, 2007
    Co-Authors: Evertjan Wils, Bob Lowenberg, Eric Braakman, Georges M G M Verjans, Elwin J C Rombouts, Annoek E C Broers, H G M Niesters, Gerard Wagemaker, Frank J T Staal, Hergen Spits
    Abstract:

    Deficient thymopoiesis and retarded Recovery of newly developed CD4+ T Cells is one of the most important determinants of impaired immunocompetence after hemopoietic stem Cell transplantation. Here we evaluated whether Fms-like tyrosine kinase 3 (Flt3) ligand (FL) alone or combined with IL-7 affects T Cell Recovery, thymopoiesis, and lymphoid progenitor expansion following bone marrow transplantation in immunodeficient mice. FL strongly accelerated and enhanced the Recovery of peripheral T Cells after transplantation of a low number of bone marrow Cells. An additive effect on T Cell Recovery was not observed after coadministration of IL-7. Lineage−sca-1+c-kit+flt3+ lymphoid progenitor Cell numbers were significantly increased in bone marrow of FL-treated mice before Recovery of thymopoiesis. Thymocyte differentiation was advanced to more mature stages after FL treatment. Improved T Cell Recovery resulted in better immunocompetence against a post-bone marrow transplantation murine CMV infection. Collectively, our data suggest that FL promotes T Cell Recovery by enhanced thymopoiesis and by expansion of lymphoid progenitors.

  • interleukin 7 improves t Cell Recovery after experimental t Cell depleted bone marrow transplantation in t Cell deficient mice by strong expansion of recent thymic emigrants
    Blood, 2003
    Co-Authors: Anna Elisabeth Clasine Broers, Sandra Posthumusvan J Sluijs, Hergen Spits, Bronno Van Der Holt, Bob Lowenberg, Eric Braakman, Jan J Cornelissen
    Abstract:

    Interleukin-7 (IL-7) has been shown to enhance thymic output of newly developed T Cells following bone marrow transplantation (BMT) in mice. In addition, IL-7 may affect peripheral expansion of T Cells. In order to study the relative contribution of thymopoiesis versus peripheral T-Cell expansion in the setting of compromised thymopoiesis, we have applied IL-7 in an experimental stem Cell transplantation model using T Cell–deficient RAG-1 / mice. C57BL/6 RAG-1/ mice received transplants of syngeneic T-Cell–depleted (TCD) bone marrow (Ly5.1) with or without supplemented T Cells (Ly5.2). IL-7 was administered until day 63 after BMT. Peripheral blood T- and B-Cell Recovery was quantified by flow cytometry and thymopoiesis was studied by quantification of T-Cell receptor rearrangement excision circles (TRECs). In mice receiving a T-Cell– replete BMT, IL-7 selectively expanded mature CD45.2 T Cells without affecting the Recovery of new bone marrow–derived CD45.1 T Cells. In contrast, IL-7 significantly enhanced the Recovery of bone marrow–derived T Cells after TCD BMT. Quantification of TRECs in mice receiving a TCD BMT revealed that enhanced T-Cell Recovery following IL-7 treatment resulted from a strong expansion of newly developed naive T Cells. These results suggest that peripheral expansion of recent thymic emigrants or mature T Cells may be a preferential mechanism by which IL-7 enhances T-Cell Recovery after BMT. (Blood. 2003;102:1534-1540)

Ross Perko - One of the best experts on this subject based on the ideXlab platform.

  • gamma delta t Cell reconstitution is associated with fewer infections and improved event free survival after hematopoietic stem Cell transplantation for pediatric leukemia
    Biology of Blood and Marrow Transplantation, 2015
    Co-Authors: Ross Perko, Guolian Kang, Anusha Sunkara, Wing Leung, Paul G Thomas, Mari Hashitate Dallas
    Abstract:

    Abstract After hematopoietic stem Cell transplantation (HSCT), successful engraftment and immune Recovery is necessary to protect the patient from relapse and infection. Many studies highlight the importance of conventional αβ T Cell Recovery after HSCT, but the impact of γδ T Cell Recovery has not been well described. Here, we investigate the Recovery of γδ T Cells in 102 pediatric patients with acute leukemia in first clinical remission who underwent allogeneic HSCT at St. Jude Children's Research Hospital from 1996 to 2011. Mean patient age was 10.5 ± 5.9 years (range, .6 to 25.2), and mean survivor follow-up was 2.7 ± 1.8 years (range, .12 to 6.0). Diagnoses included 59% patients with acute lymphoblastic leukemia and 41% patients with acute myelogenous leukemia. Multivariate analysis demonstrated significant impact of the maximum number of CD3+, CD4+, and CD8+ T Cells and donor source on the γδ T Cell Recovery (P

  • gamma delta t Cell reconstitution is associated with fewer infections and improved event free survival after hematopoietic stem Cell transplantation for pediatric leukemia
    Biology of Blood and Marrow Transplantation, 2015
    Co-Authors: Ross Perko, Guolian Kang, Anusha Sunkara, Wing Leung, Paul G Thomas, Mari Hashitate Dallas
    Abstract:

    Abstract After hematopoietic stem Cell transplantation (HSCT), successful engraftment and immune Recovery is necessary to protect the patient from relapse and infection. Many studies highlight the importance of conventional αβ T Cell Recovery after HSCT, but the impact of γδ T Cell Recovery has not been well described. Here, we investigate the Recovery of γδ T Cells in 102 pediatric patients with acute leukemia in first clinical remission who underwent allogeneic HSCT at St. Jude Children's Research Hospital from 1996 to 2011. Mean patient age was 10.5 ± 5.9 years (range, .6 to 25.2), and mean survivor follow-up was 2.7 ± 1.8 years (range, .12 to 6.0). Diagnoses included 59% patients with acute lymphoblastic leukemia and 41% patients with acute myelogenous leukemia. Multivariate analysis demonstrated significant impact of the maximum number of CD3 + , CD4 + , and CD8 + T Cells and donor source on the γδ T Cell Recovery ( P P P P P  = .026 and P  = .02, respectively). We found the probability of infections for patients with an elevated number of γδ T Cells was significantly lower compared with patients with low or normal γδ T Cells after HSCT (18% versus 54%; P  = .025). Bacterial infections were not observed in patients with elevated γδ T Cells. Finally, event-free survival was significantly higher in patients with enhanced γδ T Cell reconstitution compared with patients with low/normal γδ T Cell reconstitution after HSCT (91% versus 55%; P  = .04). Thus, γδ T Cells may play an important role in immune reconstitution after HSCT.

Adam M Dimmick - One of the best experts on this subject based on the ideXlab platform.

  • fast and label free isolation of circulating tumor Cells from blood from a research microfluidic platform to an automated fluidic instrument vtx 1 liquid biopsy system
    SLAS TECHNOLOGY: Translating Life Sciences Innovation, 2018
    Co-Authors: Clementine A Lemaire, Sean Z Liu, Charles Wilkerson, Vishnu C Ramani, Nasim Barzanian, Kuowei Huang, James Che, Michael W Chiu, Meghah Vuppalapaty, Adam M Dimmick
    Abstract:

    Tumor tissue biopsies are invasive, costly, and collect a limited Cell population not completely reflective of patient cancer Cell diversity. Circulating tumor Cells (CTCs) can be isolated from a simple blood draw and may be representative of the diverse biology from multiple tumor sites. The VTX-1 Liquid Biopsy System was designed to automate the isolation of clinically relevant CTC populations, making the CTCs available for easy analysis. We present here the transition from a cutting-edge microfluidic innovation in the lab to a commercial, automated system for isolating CTCs directly from whole blood. As the technology evolved into a commercial system, flexible polydimethylsiloxane microfluidic chips were replaced by rigid poly(methyl methacrylate) chips for a 2.2-fold increase in Cell Recovery. Automating the fluidic processing with the VTX-1 further improved cancer Cell Recovery by nearly 1.4-fold, with a 2.8-fold decrease in contaminating white blood Cells and overall improved reproducibility. Two isolation protocols were optimized that favor either the cancer Cell Recovery (up to 71.6% Recovery) or sample purity (≤100 white blood Cells/mL). The VTX-1's performance was further tested with three different spiked breast or lung cancer Cell lines, with 69.0% to 79.5% Cell Recovery. Finally, several cancer research applications are presented using the commercial VTX-1 system.

  • fast and label free isolation of circulating tumor Cells from blood from a research microfluidic platform to an automated fluidic instrument vtx 1 liquid biopsy system
    SLAS TECHNOLOGY: Translating Life Sciences Innovation, 2018
    Co-Authors: Clementine A Lemaire, Vishnu C Ramani, Nasim Barzanian, Kuowei Huang, Michael W Chiu, Meghah Vuppalapaty, Adam M Dimmick, Charles L Wilkerson, Dino Di Carlo, Michael L Kochersperger
    Abstract:

    Tumor tissue biopsies are invasive, costly, and collect a limited Cell population not completely reflective of patient cancer Cell diversity. Circulating tumor Cells (CTCs) can be isolated from a simple blood draw and may be representative of the diverse biology from multiple tumor sites. The VTX-1 Liquid Biopsy System was designed to automate the isolation of clinically relevant CTC populations, making the CTCs available for easy analysis. We present here the transition from a cutting-edge microfluidic innovation in the lab to a commercial, automated system for isolating CTCs directly from whole blood. As the technology evolved into a commercial system, flexible polydimethylsiloxane microfluidic chips were replaced by rigid poly(methyl methacrylate) chips for a 2.2-fold increase in Cell Recovery. Automating the fluidic processing with the VTX-1 further improved cancer Cell Recovery by nearly 1.4-fold, with a 2.8-fold decrease in contaminating white blood Cells and overall improved reproducibility. Two is...